Evidence map›Paper›PMID 34636997›Full record

ReviewHuman genetics2022

How to fix a broken protein: restoring function to mutant human cystathionine β-synthase.

Warren D Kruger

Open access · greenAbstract readReview
In one paragraph

Review in Human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. HCellular and molecular life sciences : CMLS · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Warren D KrugerCancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA. warren.kruger@fccc.edu.ORCID http://orcid.org/0000-0002-4990-3695
Fox Chase Cancer Center · US

Funding

GENETIC MODULATION OF CBS TO LOWER PLASMA HOMOCYSTEINER01HL057299 · NHLBI · FOX CHASE CANCER CENTER · PI KRUGER, WARREN D · 2001 to 2009
$3.2M
Treatment of CBS Deficiency with Proteostasis ModulatorsR01DK101404 · NIDDK · RESEARCH INST OF FOX CHASE CAN CTR · PI KRUGER, WARREN D · 2014 to 2020
$3.0M
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and EpigeneticsR01GM098772 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI KRUGER, WARREN D · 2012 to 2015
$1.4M
Foundation for the National Institutes of Health DK101404NHLBI NIH HHS R01 HL057299NIDDK NIH HHS R01 DK101404NIGMS NIH HHS R01 GM098772
6 · The paper itself

Abstract

Inborn errors of metabolism (IEM) comprise a large class of recessive genetic diseases involving disorders of cellular metabolism that tend to be caused by missense mutations in which a single incorrect amino acid is substituted in the polypeptide chain. Cystathionine beta-synthase (CBS) deficiency is an example of an IEM that causes large elevations of blood total homocysteine levels, resulting in phenotypes in several tissues. Current treatment strategies involve dietary restriction and vitamin therapy, but these are only partially effective and do not work in all patients. Over 85% of the described mutations in CBS-deficient patients are missense mutations in which the mutant protein fails to fold into an active conformation. The ability of CBS to achieve an active conformation is affected by a variety of intracellular protein networks including the chaperone system and the ubiquitin/proteasome system, collectively referred to as the proteostasis network. Proteostasis modulators are drugs that perturb various aspects of these networks. In this article, we will review the evidence that modulation of the intracellular protein folding environment can be used as a potential therapeutic strategy to treat CBS deficiency and discuss the pros and cons of such a strategy.

Indexed as

Cystathionine beta-SynthaseHomocystinuriaHumansMolecular ChaperonesMutationPhenotypeCystathionine beta-SynthaseMolecular Chaperones

Identifiers

PMID34636997
PMCPMC9003067
OpenAlexW3206019105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.